Blink Health drops Express Scripts in dispute over insulin prices

A corporate dispute over a price-discount program for diabetes patients taking Eli Lilly & Co.’s insulin has resulted in an industry middleman’s exit from the deal — the latest sign of discord among players in a prescription-drug supply chain facing criticism for high prices.